Retatrutide Research: The Triple GIP/GLP-1/Glucagon Agonist Explained (2026)

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide engineered as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Developed by Eli Lilly and first characterized in preclinical work published by Coskun et al. (2022), it is the furthest-developed compound in the incretin-triple-agonist research class, with phase 2 results published in the New England Journal of Medicine (Jastreboff et al., 2023) and The Lancet (Rosenstock et al., 2023).

This research summary reviews retatrutide's published mechanism, trial history, and laboratory-handling context for Canadian researchers. Retatrutide is an investigational research compound and is not an approved therapeutic in any jurisdiction. All observations summarized below describe outcomes in published trial participants, not therapeutic claims.

Key Takeaways

• Retatrutide engages three hormone receptors in a single peptide: GIP, GLP-1, and glucagon (Coskun et al., 2022).
• The phase 2 obesity trial (Jastreboff et al., 2023) documented body-composition changes in trial participants of up to -24.2% from baseline at 48 weeks in the highest-dose arm.
• The phase 2 type 2 diabetes trial (Rosenstock et al., 2023) reported HbA1c and body-weight parameters across placebo, dulaglutide-comparator, and four retatrutide arms.
• Retatrutide is supplied as a lyophilized powder for research use and reconstituted with bacteriostatic water in a laboratory context.
• It is not approved by Health Canada, the FDA, or the EMA for any therapeutic indication; phase 3 trials (TRIUMPH program) are ongoing as of 2026.

Background

Retatrutide was developed by Eli Lilly as part of the broader incretin-agonist research program that produced tirzepatide — the first clinically validated dual GIP/GLP-1 agonist. The discovery hypothesis, articulated by Coskun et al. (2022), was that adding glucagon-receptor agonism to dual GIP/GLP-1 engagement could probe whether hepatic lipolysis and increased basal energy expenditure — pathways glucagon-receptor activation engages in published metabolic models — would add mechanistically to the incretin axis.

The compound is a single 39-amino-acid peptide derived from the GIP sequence, modified with a C-20 fatty diacid moiety to enable serum-albumin binding and extend plasma half-life to approximately six days in published pharmacokinetic studies (Coskun et al., 2022). The engineering objective was balanced receptor engagement: retatrutide shows comparable potency at all three receptors in cell-based cAMP-accumulation assays, a distinct pharmacological profile from the GIP-biased tirzepatide or the GLP-1-selective semaglutide.

In the broader incretin-agonist taxonomy — covered in depth in the GLP-1 peptides Canadian researcher's guide — retatrutide sits in the triple-agonist class, one step beyond dual agonists like tirzepatide and two steps beyond single agonists like semaglutide. Phase 1 results were first published in 2022; phase 2 results for obesity and for type 2 diabetes were published in 2023; the TRIUMPH phase 3 program was initiated in 2023 and remains ongoing.

Mechanism of Action

Retatrutide engages three G protein-coupled receptors simultaneously. Each pathway contributes a distinct mechanism that has been studied independently in the published literature.

GLP-1 receptor agonism activates the Gs-cAMP-PKA cascade in pancreatic beta cells, amplifying glucose-dependent insulin secretion. In the central nervous system, GLP-1R activation in hypothalamic arcuate nucleus and brainstem regions (nucleus of the solitary tract, area postrema) has been studied in the context of satiety and food-intake regulation (Drucker, 2018). This is the mechanistic backbone retatrutide shares with semaglutide.

GIP receptor agonism activates adipose-tissue and pancreatic pathways that complement GLP-1 signaling. In published adipocyte research, GIP-receptor activation has been studied in the context of insulin-sensitized lipid storage and nutrient partitioning (Coskun et al., 2018). Tirzepatide was the first compound to demonstrate that dual engagement produced distinct trial outcomes from GLP-1 mono-agonism at comparable receptor occupancy.

Glucagon receptor agonism is the mechanistic novelty of retatrutide. Glucagon-receptor activation in hepatic research models increases lipolysis, stimulates basal energy expenditure, and alters amino-acid metabolism (Coskun et al., 2022). Glucagon-receptor agonism in isolation is studied cautiously because it raises blood glucose in non-GLP-1-paired contexts; the mechanistic rationale for a triple agonist is that concurrent GLP-1 and GIP engagement offsets the glycemic liability of glucagon-receptor activation while capturing the lipolytic and thermogenic pathways.

This differs from tirzepatide (dual GIP/GLP-1, no glucagon-receptor engagement) and from semaglutide (GLP-1 selective, no GIP or glucagon-receptor engagement). In cell-based signaling assays, retatrutide's balanced three-receptor activation profile is the defining pharmacological feature (Coskun et al., 2022).

Key Research Findings

Phase 1 Dose-Ranging Study

The phase 1 first-in-human dose-ranging study was reported alongside the preclinical characterization in Coskun et al. (2022) in Cell Metabolism. Single and multiple-ascending-dose cohorts established the pharmacokinetic profile — approximately six-day half-life, enabling weekly dosing — and the initial safety and tolerability observations in the trial population.

Phase 2 Obesity Trial (Jastreboff et al., 2023)

The phase 2 obesity trial published by Jastreboff et al. (2023) in the New England Journal of Medicine enrolled 338 adults with a body-mass index of 30 or greater, or 27 or greater with at least one weight-related comorbidity, without diabetes. Participants were randomly assigned to placebo or to retatrutide at escalating weekly subcutaneous doses: 1mg, 4mg (with 2mg and 4mg starting-dose groups), 8mg (with 2mg and 4mg starting-dose groups), or 12mg (with 2mg and 4mg starting-dose groups), for a total of 48 weeks.

The trial reported least-squares mean percent change in body weight from baseline at 48 weeks as follows: placebo -2.1%, retatrutide 1mg -8.7%, 4mg -17.1%, 8mg -22.8%, and 12mg -24.2%. The 12mg group's mean percent change in body weight of -24.2% was the largest reported in any published incretin-class phase 2 trial to date (Jastreboff et al., 2023). Gastrointestinal adverse events — nausea, diarrhea, vomiting, and constipation — were the most commonly reported tolerability events across dose groups, and treatment discontinuation due to adverse events occurred in 6-16% of retatrutide participants versus 1% in the placebo group. All outcomes describe observations in trial participants as reported; they are not therapeutic claims and not generalizable outside the trial population.

Phase 2 Type 2 Diabetes Trial (Rosenstock et al., 2023)

The parallel phase 2 type 2 diabetes trial published by Rosenstock et al. (2023) in The Lancet enrolled 281 adults with type 2 diabetes on stable metformin monotherapy. Participants were randomly assigned to placebo, to dulaglutide 1.5mg weekly as an active comparator, or to retatrutide at 0.5mg, 4mg (with starting-dose regimens), 8mg, or 12mg weekly, for 36 weeks.

The trial reported changes in HbA1c and body weight across arms. At 36 weeks, HbA1c reductions from baseline were -0.01% with placebo, -1.41% with dulaglutide 1.5mg, -1.39% with retatrutide 0.5mg, and up to -2.02% with retatrutide 12mg. Body-weight changes from baseline ranged from +3.0% (placebo) to -16.94% (retatrutide 12mg). Tolerability observations were consistent with the obesity trial — gastrointestinal events the most common, dose-dependent (Rosenstock et al., 2023).

TRIUMPH Phase 3 Program

The TRIUMPH phase 3 program launched in 2023 with multiple trials evaluating retatrutide across obesity, type 2 diabetes, cardiovascular outcomes, and adjacent endpoints. As of 2026, phase 3 readouts are pending. The published phase 2 data remain the current evidence base for the compound.

Methodology Notes

Research-grade retatrutide is supplied as a lyophilized powder under inert atmosphere in sealed glass vials. PinPoint stocks vial formats ranging from 5mg through 60mg on the retatrutide product page. Each batch ships with a third-party Certificate of Analysis documenting HPLC purity (98%+), mass-spectrometry identity confirmation matching the expected monoisotopic mass, and endotoxin levels.

Reconstitution

Reconstitution is performed with bacteriostatic water (0.9% benzyl alcohol) introduced slowly down the inner vial wall, allowing the lyophilized cake to dissolve without agitation. Vortexing is avoided; gentle swirling is the documented norm for GLP-1-family research peptides. The target research concentration depends on the experimental protocol — the reconstitution calculator computes solvent volume for any target stock concentration across available vial sizes. For the general protocol, see the peptide reconstitution guide.

Storage

Lyophilized retatrutide stored at -20°C in the unopened vial remains stable for the duration of the documented shelf life, typically 24 months from manufacture. Post-reconstitution storage is refrigerated (2-8°C) with a documented stability window of approximately 28 days, consistent with other GLP-1-family research peptides. Repeated freeze-thaw cycles are avoided.

Identity and Purity Verification

The COA's three key lines for retatrutide are: HPLC purity (confirm 98% or higher), mass-spec identity (the monoisotopic mass should match the expected value within accepted tolerance), and endotoxin level (for in vivo research applications, typically under 10 EU/mg). For a full walkthrough of how to read these documents, see how to read a peptide Certificate of Analysis.

Comparison with Tirzepatide and Semaglutide in Published Research

Head-to-head trials of retatrutide against tirzepatide or semaglutide have not been published as of early 2026. The available cross-trial comparisons are indirect and must be interpreted with caution: trial populations, durations, and endpoints differ between the SURMOUNT (tirzepatide), STEP (semaglutide), and Jastreboff-2023 (retatrutide) programs.

With that caveat, the phase 2/phase 3 body-composition observations across the three compounds have been summarized in the published literature as follows: semaglutide 2.4mg weekly reported mean body-weight change from baseline of -14.9% at 68 weeks (Wilding et al., 2021, STEP 1); tirzepatide 15mg weekly reported -20.9% at 72 weeks (Jastreboff et al., 2022, SURMOUNT-1); retatrutide 12mg weekly reported -24.2% at 48 weeks (Jastreboff et al., 2023, phase 2). These are observations in distinct trial populations and cannot be interpreted as a head-to-head comparison.

Mechanistically, the pharmacological distinction is clearer than any cross-trial endpoint comparison. Semaglutide is a GLP-1 mono-agonist. Tirzepatide is a dual GIP/GLP-1 agonist with GIP-biased signaling (Willard et al., 2020). Retatrutide is a balanced triple agonist at GIP, GLP-1, and glucagon receptors. The three compounds engage progressively more of the incretin-and-glucagon receptor axis, and the published phase 2/phase 3 data — viewed side-by-side in trial-population context — have so far tracked that mechanistic progression.

Regulatory Context

Retatrutide is an investigational research compound. It is not approved by Health Canada for any therapeutic indication, not approved by the US Food and Drug Administration, not approved by the European Medicines Agency, and not approved in any other jurisdiction as of 2026. Phase 3 trials (TRIUMPH program) are ongoing, and regulatory submissions are expected following phase 3 readouts.

In Canada, research-grade retatrutide is supplied for laboratory research applications only. It is not for human consumption, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease. Canadian researchers sourcing retatrutide must document the research-use context per institutional or industry protocol; vendors must ship with research-use disclaimers and batch COA documentation. For the full regulatory analysis of peptides in Canada, see are peptides legal in Canada.

Conclusion

Retatrutide is the furthest-developed triple GIP/GLP-1/glucagon receptor agonist in the published research literature. Its pharmacological distinction is balanced engagement of all three receptors in a single peptide, and its phase 2 data — published in the New England Journal of Medicine and The Lancet — established the largest observed body-composition and glycemic parameter changes yet reported for an incretin-class research compound at the tested doses and durations. Phase 3 TRIUMPH data are pending.

For Canadian researchers working with retatrutide, the handling methodology parallels the broader GLP-1 family: lyophilized-format supply, bacteriostatic-water reconstitution, refrigerated post-reconstitution storage, and COA-verified identity and purity. Retatrutide research is research — not therapeutic guidance — and all observations described here derive from published trial populations.

References

1. Coskun, T., et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept." Cell Metabolism 34.9 (2022): 1234-1247.
2. Jastreboff, A.M., et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." New England Journal of Medicine 389.6 (2023): 514-526.
3. Rosenstock, J., et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet 402.10401 (2023): 529-544.
4. Coskun, T., et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept." Molecular Metabolism 18 (2018): 3-14.
5. Drucker, D.J. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27.4 (2018): 740-756.
6. Jastreboff, A.M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.
7. Wilding, J.P.H., et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine 384.11 (2021): 989-1002.
8. Willard, F.S., et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight 5.17 (2020): e140532.

Related Resources

• Retatrutide — research-grade vials, COA verified
• Browse the full GLP-1 peptide catalog
• GLP-1 peptides: a Canadian researcher's guide to the incretin family
• Semaglutide: GLP-1 receptor agonist clinical research
• How to read a peptide Certificate of Analysis
• Peptide reconstitution guide
• Reconstitution calculator

---

For research purposes only. Not for human consumption. This product is not a drug, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease. Must be 18+ to purchase. PinPoint Peptides is not a pharmacy and does not provide medical advice.